T1	Participants 25 37	hypertension
T2	Participants 326 439	evaluated primarily by means of MEMS (Medication Event Monitoring System, Aprex Corporation, Fremont, California)
T3	Participants 1020 1115	One hundred and seven subjects between the ages of 26 and 80 participated in the clinical trial
